Companies › Lantu Biopharma
2 active drug programs in 2 registered trials: 2 Phase 1; Hematology, Neurology; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Vebeglogene autotemcel Autologous HSPCs transduced with lentiviral vector encoding functional HBB gene | – | Phase 1 | Beta-Thalassemia | Aug 2027 |
| vesemnogene lantuparvovec AAV-mediated SMN1 gene delivery | SMN1 | Phase 1 | Spinal Muscular Atrophy | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06308159 | Vebeglogene autotemcel | Phase 1 | Beta-Thalassemia | Hematology | Aug 2027 |
| NCT06288230 | vesemnogene lantuparvovec | Phase 1 | Spinal Muscular Atrophy | Neurology | Oct 2027 |
Novartis Gemma Biotherapeutics GeneCradle Lanyue Biotech (Hangzhou) Biocad
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.